About: Therapeutic effects of dipyridamole on COVID-19 patients with coagulation dysfunction

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Therapeutic effects of dipyridamole on COVID-19 patients with coagulation dysfunction Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Therapeutic effects of dipyridamole on COVID-19 patients with coagulation dysfunction
Creator	Zhao, Jincun Li, Zhe Zhang, Qingling Wang, Jun Liu, Shuai Xu, Yanhui Zhou, Fuling Huang, Hui Chen, Cui, Jun Luo, Hai-Bin Zhang, Yuxia Lew, Andrew Bai, Fang, Rongli Liu, Xiaoyan Ou, Changxing Shi, Yinyi Xian, Huifang Xiong, Bei Zhao, Zhiyao
Source	MedRxiv
abstract	The human coronavirus HCoV-19 infection can cause acute respiratory distress syndrome (ARDS), hypercoagulability, hypertension, extrapulmonary multiorgan dysfunction. Effective antiviral and anti-coagulation agents with safe clinical profiles are urgently needed to improve the overall prognosis. We screened an FDA approved drug library and found that an anticoagulant agent dipyridamole (DIP) suppressed HCoV-19 replication at an EC50 of 100 nM in vitro. It also elicited potent type I interferon responses and ameliorated lung pathology in a viral pneumonia model. In analysis of twelve HCoV-19 infected patients with prophylactic anti-coagulation therapy, we found that DIP supplementation was associated with significantly increased platelet and lymphocyte counts and decreased D-dimer levels in comparison to control patients. Two weeks after initiation of DIP treatment, 3 of the 6 severe cases (60%) and all 4 of the mild cases (100%) were discharged from the hospital. One critically ill patient with extremely high levels of D-dimer and lymphopenia at the time of receiving DIP passed away. All other patients were in clinical remission. In summary, HCoV-19 infected patients could potentially benefit from DIP adjunctive therapy by reducing viral replication, suppressing hypercoagulability and enhancing immune recovery. Larger scale clinical trials of DIP are needed to validate these therapeutic effects.
has issue date	2020-02-29(xsd:dateTime)
bibo:doi	10.1101/2020.02.27.20027557
has license	medrxiv
sha1sum (hex)	2d0285c90976dfa43d58eca6b7d1d7ef29994fc2
schema:url	https://doi.org/10.1101/2020.02.27.20027557
resource representing a document's title	Therapeutic effects of dipyridamole on COVID-19 patients with coagulation dysfunction
resource representing a document's body	covid:2d0285c90976dfa43d58eca6b7d1d7ef29994fc2#body_text
is schema:about of	named entity 'scale' named entity 'patient' named entity 'receiving' named entity 'COVID-19' covid:arg/2d0285c90976dfa43d58eca6b7d1d7ef29994fc2 named entity 'One' named entity 'acute respiratory distress syndrome' named entity 'cases' named entity 'extremely' named entity 'infection' named entity 'coronavirus' named entity 'ARDS' named entity 'needed' named entity 'anti-coagulation' named entity 'lung' named entity 'hypercoagulability' named entity 'levels' named entity 'adjunctive therapy' named entity 'pathology' named entity 'validate' named entity 'recovery' named entity 'D-dimer' named entity 'profiles' named entity 'screened' named entity 'replication' named entity 'weeks' named entity 'Therapeutic' named entity 'lymphopenia' named entity 'dipyridamole' named entity 'control patients' named entity 'anti-coagulation' named entity 'anti-coagulation therapy' named entity 'viral replication' named entity 'human coronavirus' named entity 'platelet' named entity 'EC50' named entity 'high levels' named entity 'coagulation' named entity 'dipyridamole' named entity 'levels' named entity 'needed' named entity 'control group' named entity 'thermodynamic cycle' named entity 'medRxiv' named entity 'February 8' named entity 'coronavirus' named entity 'D-dimer' named entity 'acute injury' named entity 'medRxiv' named entity 'Mpro' named entity 'medRxiv' named entity 'medRxiv' named entity 'medRxiv' named entity 'protease' named entity 'levels of evidence' named entity 'Biacore' named entity 'fibrosis' named entity 'medRxiv' named entity 'control group' named entity 'Mpro' named entity 'SPR' named entity 'proteinases' named entity 'critically ill patients' named entity 'survival rate' named entity 'South Korea'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software